GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (LTS:0T6G) » Definitions » Capital Expenditure

Homology Medicines (LTS:0T6G) Capital Expenditure : $-0.23 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Homology Medicines's cash flow for capital expenditures for the three months ended in Dec. 2023 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.23 Mil.


Homology Medicines Capital Expenditure Historical Data

The historical data trend for Homology Medicines's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Capital Expenditure Chart

Homology Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial -21.83 -3.73 -2.40 -1.29 -0.23

Homology Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.23 - - -

Homology Medicines Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Homology Medicines (LTS:0T6G) Business Description

Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (LTS:0T6G) Headlines

No Headlines